Aflibercept 8 mg for diabetic macular edema: 48-week results from the Phase 2/3 PHOTON trial
May 17th 2023Diana V. Do, MD, presented details of the PHOTON study at the Association for Research in Vision and Ophthalmology annual meeting, held recently in New Orleans, highlighting the safety and efficacy of 8 milligrams of aflibercept.
ARVO 2023: Implementing dropless cataract surgery to drop the cost
May 3rd 2023Ravi Parikh, MD, MPH, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation about adopting dropless cataract surgery to help reduce cost to both patients and the healthcare system at this year's ARVO meeting.
ARVO 2023: Machine learning to identify structural phenotypes for glaucoma
May 3rd 2023Nazlee Zebardast, MD, MSc sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss her research on using machine learning methods to identify image-based, specifically OCT based, phenotypes or structural phenotypes for glaucoma. at this year's ARVO meeting.
ARVO 2023: ViaLase's FLigHT for non-incisional glaucoma treatment
May 3rd 2023Eric Mikula, PhD, from ViaLase sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss the company's femtosecond laser image-guided high-precision trabeculectomy, FLigHT, for non-incisional glaucoma treatment at this year's ARVO meeting.
ARVO LIVE: Using mitochondria, senolytic agents to treat retinal injury
May 3rd 2023Ram Kannan, PhD, FARVO, principal investigator and adjunct professor of Ophthalmology at David Geffen School of Medicine, UCLA, Doheny Eye Institute, made a pair of presentations at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans. He offers some of the highlights in a conversation with Ophthalmology Times.
ARVO LIVE: CEO of RetinAI gives update on technological advances in ophthalmology
May 2nd 2023Ophthalmology Times® talked with Carlos Ciller, PhD, the co-founder and CEO of RetinAI, about technological advances the company is making to drive innovation and to accelerate drug development pipelines at this year's ARVO meeting.
ARVO LIVE: AI revolution in ophthalmology
May 2nd 2023Ophthalmology Times® talked with AnnMarie Hipsley, DPT, PhD, about 3D finite element model used to understand more about the biomechanics of accommodation and dis-accommodation as it relates to functions for visual function as well as aqueous hydrodynamics at this year's ARVO meeting.
ARVO 2023: Ashvattha Therapeutics presents preclinical data on anti-VEGF nanomedicine D-4517.2
April 27th 2023The company shared data at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans that demonstrated that a single oral dose of D-4517.2 significantly reduced choroidal neovascularization lesions to a level comparable to D-4517.2 delivered subcutaneously and aflibercept administered intravitreally at the same mass dose in a laser-induced CNV mouse model.